Log in to search using one of your social media accounts:

 

Viekira Pak Results Reassuring for Compensated CirrhosisViekira Pak Results Reassuring for Compensated Cirrhosis

For patients with genotype 1 hepatitis C infection and cirrhosis, the combination of ombitasvir, paritaprevir, and ritonavir plus dasabuvir, with or without ribavirin, is safe and effective. Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Related Links:

CONCLUSIONS: In recent years, improvements in surgical techniques and immunosuppressive therapies have helped prolong survival of patients who undergo liver transplant. However, this also has led to a rise in the incidence of long-term complications such as de novo malignancy. These patients are more likely to develop de novo malignancy than the general population, for which chronic immunosuppression is identified as a major risk factor. Early diagnosis and treatment of de novo malignancies can help obtain better prognosis and higher survival rates in these patients. PMID: 29237362 [PubMed - as supplied by publisher]
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - Category: Transplant Surgery Authors: Tags: Exp Clin Transplant Source Type: research
This article is protected by copyright. All rights reserved.
Source: Journal of Viral Hepatitis - Category: Infectious Diseases Authors: Tags: Original Paper Source Type: research
Authors: Uojima H, Murakami S, Nakatani S, Hidaka H, Takeuchi A, Tanaka Y, Inoue T, Yamane K, Kubota K, Nakazawa T, Shibuya A, Tanaka Y, Koizumi W Abstract There have been few studies on relapse after a sustained virological response in hepatitis C virus (HCV) patients treated with interferon-free regimens. Thus, the risk of late relapse in patients treated with interferon-free therapy remains unclear. A 67-year-old woman with HCV genotype 1b and liver cirrhosis received oral daclatasvir and asunaprevir. Combination therapy was stopped after 4 weeks because of an episode of encephalopathy. Nonetheless, an HCV polym...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Hepatitis C virus (HCV) infection is a major cause of viral hepatitis with a global seroprevalence estimated to be greater than 185 million [1]. Approximately 75% to 85% of patients with HCV infection develop a chronic hepatitis C (CHC) infection [2]. In addition to the direct negative impact by the virus on the liver, where more than 40% of CHC infections leads to liver cirrhosis after 30 years [3], CHC infection is also associated with extrahepatic manifestations including kidney disease, most commonly membranoproliferative glomerulonephritis with or without cryoglobulinemia [4].
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
Opinion statementWith the recent introduction of direct acting antiviral agents for hepatitis C treatment, many patients are receiving these highly effective therapies. Patients with advanced fibrosis or cirrhosis prior to antiviral treatment will have decreased but persistent risk of hepatocellular carcinoma following cure of hepatitis C. This review will discuss this risk and review current surveillance recommendations.
Source: Current Treatment Options in Infectious Diseases - Category: Infectious Diseases Source Type: research
ObjectivesStudies evaluating the efficacy and safety of the fixed‐dose combination ledipasvir (LDV)/sofosbuvir (SOF) in patients coinfected with HIV‐1 and hepatitis C virus (HCV) have mainly included treatment‐naïve patients without cirrhosis. We aimed to evaluate the efficacy and safety of this combination in treatment‐experienced patients with and without cirrhosis. MethodsWe conducted a multicentre, open‐label, double‐arm, nonrandomized study in patients coinfected with HIV‐1 and HCV genotype 1 with and without cirrhosis, who had good viral suppression on their antiretroviral regimens. All patients we...
Source: HIV Medicine - Category: Infectious Diseases Authors: Tags: Original Research Source Type: research
Non-alcoholic fatty liver disease (NAFLD) comprising non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), together with their complications of cirrhosis, liver failure and liver cancer will be the predominant liver disease for the conceivable future. Traditionally, viral hepatitis has been the focus of basic and clinical research, and the bread and butter for clinicians in the field. However, with the advent of therapies that suppress hepatitis B virus replication and the shift in standard of care for the treatment of hepatitis C to highly effective direct acting antivirals, the focus of clinical prac...
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Editorial Source Type: research
Publication date: Available online 6 December 2017 Source:Revista Clínica Española (English Edition) Author(s): M.J. Vivancos, A. Moreno, C. Quereda Hepatitis C virus infection is a significant public health problem. The introduction of direct-acting antiviral agents, whose efficacy is greater than 90% in all patient groups (including those with cirrhosis), has represented a highly relevant change compared with classical interferon-based therapies. Tolerance for these antiviral agents is significantly better, and the treatment duration is shorter. This review updates the treatment of hepatitis C virus infect...
Source: Revista Clinica Espanola - Category: Internal Medicine Source Type: research
Summary BackgroundAntiviral therapy for hepatitis C has the potential to improve liver function in patients with decompensated cirrhosis. AimsTo examine the virological response and effect of viral clearance in patients with decompensated hepatitis C cirrhosis all with MELD scores ≥15 following sofosbuvir/daclatasvir ± ribavirin. MethodsWe prospectively collected data on patients who commenced sofosbuvir/daclatasvir for 24‐weeks under the Australian patient supply program (TOSCAR) and analysed outcomes including sustained viral response at 12 weeks (SVR12), death and transplant. Results108 patients (M/F, 79/29;...
Source: Alimentary Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Tags: ORIGINAL ARTICLE Source Type: research
ConclusionsIFN‐free direct‐acting antiviral therapy of chronic hepatitis C does not alter the short‐term risk for HCC in patients with liver cirrhosis. A reduced HCC incidence may become evident after more than 1.5 years of follow‐up.
Source: Alimentary Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Tags: ORIGINAL ARTICLE Source Type: research
More News: Cirrhosis | Gastroenterology | Hepatitis | Hepatitis C | Norvir